GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SMS Pharmaceuticals Ltd (NSE:SMSPHARMA) » Definitions » Debt-to-EBITDA

SMS Pharmaceuticals (NSE:SMSPHARMA) Debt-to-EBITDA : 2.18 (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is SMS Pharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

SMS Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹1,347 Mil. SMS Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹1,506 Mil. SMS Pharmaceuticals's annualized EBITDA for the quarter that ended in Sep. 2024 was ₹1,311 Mil. SMS Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 2.18.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for SMS Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

NSE:SMSPHARMA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.51   Med: 1.92   Max: 4.35
Current: 2.15

During the past 13 years, the highest Debt-to-EBITDA Ratio of SMS Pharmaceuticals was 4.35. The lowest was 1.51. And the median was 1.92.

NSE:SMSPHARMA's Debt-to-EBITDA is ranked worse than
57.16% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs NSE:SMSPHARMA: 2.15

SMS Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for SMS Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMS Pharmaceuticals Debt-to-EBITDA Chart

SMS Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.87 2.06 2.22 4.35 2.34

SMS Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.42 - 2.04 - 2.18

Competitive Comparison of SMS Pharmaceuticals's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, SMS Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SMS Pharmaceuticals's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SMS Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where SMS Pharmaceuticals's Debt-to-EBITDA falls into.



SMS Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

SMS Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1586.842 + 1220.863) / 1202.402
=2.34

SMS Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1347.3 + 1506.132) / 1310.788
=2.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


SMS Pharmaceuticals  (NSE:SMSPHARMA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


SMS Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of SMS Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


SMS Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Plot No. 72, H.No. 8-2-334/3&4, Road. No. 5, Opposite SBI Executive Enclave, Banjara Hills, Hyderabad, TG, IND, 500034
SMS Pharmaceuticals Ltd is a drug manufacturing company. It is engaged in the manufacturing and sale of active pharmaceutical ingredients (API's), and their intermediates viz. Metal Acetylacetonates, Diltiazem Hydrochloride and Taxol C-13 Side Chain. Its product portfolio includes drugs for anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, anti-viral, among others.

SMS Pharmaceuticals Headlines

No Headlines